Cambium Bio LtdASX: CMB

Quarterly Activities/Appendix 4C Cash Flow Report

Oct 28, 2026 at 3:37 AM EDT · Issued by Cambium Bio Ltd via ASX

Filed with ASX · Oct 28, 2026 at 3:37 AM EDT

On 6ix: 6ix.com/news/quarterly-activitiesappendix-4c-cash-flow-report-449

ASX Announcement 28 October 2026 Quarterly Cashflow Report & Business Update Period ending 30 September 2026 Cambium Bio Limited (ASX:CMB) (Cambium Bio or Company), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair...

View Attachment

6ix is reading this filing.

Cambium Bio Ltd on 6ix

Earlier from Cambium Bio

Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye DiseaseSep 16
Cambium Bio Secures A$10.85 Million Funding PackageSep 15
FY26 Appendix 4E and Annual ReportAug 28
Cambium Bio Raises A$1.0 Million via PlacementJul 21
FDA Confirms Single Pivotal Trial Pathway for Elate OcularApr 23

All Cambium Bio news releases

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio